8-K: INmune Bio Reviews 2025, Outlines 2026 Strategy

INmune Bio Inc. issued a shareholder letter detailing 2025 clinical milestones and strategic initiatives for 2026, focusing on CORDStrom and XPro programs.

Summary

• INmune Bio Inc. issued a shareholder letter reviewing 2025 milestones and outlining 2026 strategic initiatives.
• Significant progress was made with CORDStrom, an allogeneic umbilical cord-derived mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
• Three commercial pilot-scale manufacturing runs for CORDStrom were successfully completed at CGT Catapult in Stevenage, UK.
• A Marketing Authorization Application (MAA) for CORDStrom is planned for mid-summer 2026 with the UK's MHRA.
• A Biologics License Application (BLA) for CORDStrom is anticipated for submission to the U.S. FDA toward the end of 2026.
• XPro (XPro1595) delivered robust evidence in a Phase 2 Alzheimer's disease trial (MINDFuL), particularly in a predefined subpopulation of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100).
• In this subpopulation, XPro showed benefits versus placebo on EMACC (effect size 0.27), Neuropsychiatric Inventory (effect size 0.24), and blood levels of pTau217 (effect size 0.18) after 6 months.
• The company closed a private placement in June 2025 and expects a research and development rebate from Australia.
• Cash and cash equivalents were approximately $27.7 million as of September 30, 2025, providing funds through year-end 2026.

Sentiment

Score: 7

Explanation: The filing presents a generally positive outlook with significant clinical progress in key programs and a solid financial position. However, the lack of a broad treatment effect in the XPro trial and the inherent risks of clinical development and regulatory approval temper the overall sentiment.

Positives

• Successful completion of three commercial pilot-scale manufacturing runs for CORDStrom, preparing for regulatory filings.
• Planned MAA submission for CORDStrom to UK's MHRA by mid-summer 2026 and BLA to U.S. FDA by end of 2026.
• XPro demonstrated meaningful and biologically consistent signals in a predefined subpopulation of Alzheimer's patients (n=100) in the MINDFuL Phase 2 study.
• Observed benefits in XPro-treated subpopulation on EMACC (effect size 0.27), Neuropsychiatric Inventory (effect size 0.24), and blood pTau217 levels (effect size 0.18) after 6 months.
• XPro's cognitive signal (0.27 effect size on EMACC at 6 months) compares favorably to 18-month results of approved anti-amyloid therapies: Lecanemab (0.10-0.15) and Donanemab (~0.19).
• Biomarker and neuroimaging results for XPro support its proposed mechanism of action and a precision-medicine development strategy.
• Strong financial position with approximately $27.7 million in cash and cash equivalents as of September 30, 2025, sufficient to fund operations through year-end 2026.
• Closed a private placement in June 2025 and expects a research and development rebate from Australia.

Negatives

• The broader modified intent-to-treat population (n=200) in the MINDFuL Phase 2 Alzheimer's trial did not show a treatment effect for XPro.
• Regulatory timelines for CORDStrom (MAA and BLA) remain subject to regulatory feedback and manufacturing readiness, indicating potential for delays.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• Actual results and the timing of certain events and circumstances may differ materially from forward-looking statements due to risks and uncertainties.
• The company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding for the company to continue operations, research and development, clinical studies, and future product commercialization.
• Risks and uncertainties related to the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.
• CORDstrom, XPro1595 (XPro, pegipanermin), and INKmune have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved.

Future Outlook

The company plans to submit a Marketing Authorization Application (MAA) for CORDStrom to the UK's MHRA by mid-summer 2026, followed by a Biologics License Application (BLA) to the U.S. FDA towards the end of 2026. They also intend to work with the FDA to define a registrational development path for XPro in Alzheimer's disease, informed by the Phase 2 MINDFuL trial data. The company expects to share details from additional XPro imaging analyses and further CORDStrom-RDEB program milestones throughout 2026.

Management Comments

• "2025 was a pivotal year for our company, highlighted by compelling clinical learnings from XPro in our Phase 2 Alzheimers disease trial and significant progress advancing CORDStrom in Recessive Dystrophic Epidermolysis Bullosa (RDEB)."
• "Our focus on harnessing the innate immune system to address conditions with large unmet need and meaningful market potential continues to drive us forward."
• "The team provided detailed updates on progress toward our Marketing Authorization Application (MAA), planned for mid-summer 2026, including how we are actively managing bottlenecks both within and outside our direct control."
• "These timelines remain subject to regulatory feedback and manufacturing readiness."
• "While the broader modified intent-to-treat population (n=200) did not show a treatment effect, we observed meaningful and biologically consistent signals in a predefined subpopulation of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100)."
• "As is common in Phase 2 development, these results allow us to refine patient selection and statistical powering for the next study, and we are working with the FDA to define an appropriate registrational development path informed by these data."
• "Financially, we exit 2025 well positioned for continued execution."
• "These resources, combined with disciplined expense management, provide us with sufficient funds to last through year-end 2026, enabling us to achieve key milestones."
• "We remain at the forefront of biotechnology with two industry-leading assets: CORDStrom, a mesenchymal stromal cell platform engineered specifically for therapeutic use from inception, and XPro, a premier approach for treating complex neuroinflammatory conditions within the central nervous system."
• "While challenges remain, we are encouraged by the progress we have made and the opportunities ahead."

Industry Context

The company operates in the clinical-stage inflammation and immunology biotechnology sector, focusing on neuroinflammatory and immunologic diseases with high unmet needs. Its approach to Alzheimer's disease with XPro, targeting neuroinflammation and using a precision-medicine strategy, aligns with emerging regulatory and payer expectations, as evidenced by comparisons to approved anti-amyloid therapies like Lecanemab and Donanemab. The development of CORDStrom for RDEB addresses a systemic, multi-organ condition, highlighting the broader impact of such diseases beyond visible symptoms.

Comparison to Industry Standards

• XPro's 6-month EMACC cognitive scale effect size of 0.27 in a biomarker-defined subpopulation compares favorably to the 18-month results of approved anti-amyloid therapies: Lecanemab (CLARITY-AD) with an estimated 0.10-0.15 effect size and Donanemab (TRAILBLAZER ALZ-2) with an estimated ~0.19 effect size.
• The company notes precedents where Phase 2 Alzheimer's programs, like lecanemab's BAN2401, did not meet primary endpoints but informed subsequent successful development and approval, suggesting a common path in this complex therapeutic area.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through advancement of clinical programs and strategic financial management. Continued support is acknowledged by management.
• Patients and Families (RDEB): CORDStrom aims to improve lives by addressing the systemic pathology of Recessive Dystrophic Epidermolysis Bullosa, offering hope for a disease with high unmet needs.
• Patients and Families (Alzheimer's): XPro shows potential for a differentiated therapy for a specific subpopulation of Alzheimer's patients, offering hope for a devastating disease.
• Employees: The company's continued progress and financial stability support ongoing operations and employment.
• Regulatory Authorities (FDA, MHRA): Engaged in ongoing discussions and submissions for regulatory approvals, indicating active collaboration.

Next Steps

• Work with the FDA to define an appropriate registrational development path for XPro in Alzheimer's disease.
• Share details from additional XPro imaging analyses in the near future.
• Submit a Marketing Authorization Application (MAA) for CORDStrom to the UK's MHRA by mid-summer 2026.
• Submit a Biologics License Application (BLA) for CORDStrom to the U.S. FDA toward the end of 2026.
• Share further milestones regarding the CORDStrom-RDEB program throughout 2026.
• Continue to update shareholders on progress throughout 2026.

Key Dates

Recommendation

While INmune Bio has shown promising clinical signals for XPro in a specific Alzheimer's subpopulation and made significant manufacturing progress for CORDStrom, the broader XPro trial did not meet its primary endpoint. The company's financial runway is solid through year-end 2026, but regulatory approvals are still pending and subject to feedback and readiness. The positive clinical signals are encouraging, but the overall risk profile of a clinical-stage biotech with no approved products and mixed Phase 2 results warrants a "hold" rather than a "buy" until further definitive clinical and regulatory milestones are achieved.

Keywords

INmune Bio, INMB, Alzheimer's disease, RDEB, Recessive Dystrophic Epidermolysis Bullosa, XPro, XPro1595, CORDStrom, neuroinflammation, immunology, clinical-stage, biotechnology, mesenchymal stromal cell, soluble TNF, innate immune system, drug development, regulatory approval, FDA, MHRA, BLA, MAA, clinical trials, Phase 2, MINDFuL, pTau217, EMACC, Neuropsychiatric Inventory, cash position, private placement